To understand the clinical relevance of targeting ERRα in wild-type p53, p53 mutant (missense or GOF), and p53-deficient colon cancer patient samples, we performed direct DNA sequencing of the complete p53 genomic locus of 37 samples that came from patient-derived colon tumors. This evidence concerns the gene ESRRA and colonic neoplasm.